Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 24Myelodysplastic Syndromes 5Myeloproliferative Disorders 3Leukemia, Biphenotypic, Acute 3Leukemia, Myeloid 2Leukemia 2Blast Crisis 2Sarcoma, Myeloid 1Neoplasms by Histologic Type 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Carcinoma, Hepatocellular 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 15fludarabine 12Mycophenolic Acid 10Standard of Care 9Whole-Body Irradiation 7Tacrolimus 7venetoclax 6Specimen Handling 6Sirolimus 6Practice Guidelines as Topic 6trametinib 5Melphalan 5fludarabine phosphate 4Mesna 4Magnetic Resonance Spectroscopy 4Filgrastim 4Biopsy 4Behavior Therapy 4Azacitidine 4Thiotepa 3Peripheral Blood Stem Cell Transplantation 3GSK2636771 3Educational Status 3Crizotinib 3Busulfan 3thymoglobulin 2talquetamab 2ruxolitinib 2palbociclib 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Idarubicin × 90 days × Clear all
NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1 Recruiting
171 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡